Fig. 5: High expression of PSMB8 is a specific feature of thymic carcinomas compared to cancers of the lung and head and neck.
From: Proteasome inhibition as a potential therapeutic target in thymic cancer
A Higher immunohistochemical expression of PSMB8 than PSMB5 in 10 TC compared to (B) 5 LSCC and (C) 5 HNSCC. D Significantly higher protein levels of PSMB5 in 3 TC vs. 10 TH, 6 LSCC, and 3 HNSCC and (E) significantly higher protein levels of PSMB8 in 6 TC vs. 10 TH, 6 LSCC, and 3 HNSCC. F Immunohistochemical expression of PSMB5, PSMB8, PSMB9, and PSMB10 in a type B3 thymoma and (G) significant response of the primary cells of the same tumor to carfilzomib (PR-171) (12.5 nM for 72 h). H, I Dynamic BH3 profiling of primary cells treated with 12.5 nM carfilzomib (PR-171) for 6 h and IHC staining for PSMB5, PSMB8, PSMB9, PSMB10, BCL2, BCL-xL, and MCL-1 in two TH patient tissue samples. *p < 0.05; **p < 0.01; ***p < 0.001.
